Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ocular Therapeutix (OCUL) and Sanofi (SNY)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ocular Therapeutix (OCUL – Research Report) and Sanofi (SNY – Research Report).
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ocular Therapeutix (OCUL)
In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Ocular Therapeutix, with a price target of $20.00. The company’s shares closed last Thursday at $6.96.
According to TipRanks.com, Bancroft is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ocular Therapeutix with a $24.38 average price target, a 253.3% upside from current levels. In a report issued on February 5, RBC Capital also maintained a Buy rating on the stock with a $30.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Sanofi (SNY)
In a report released today, Steve Scala from TD Cowen maintained a Hold rating on Sanofi, with a price target of $57.00. The company’s shares closed last Thursday at $46.84, close to its 52-week low of $45.22.
According to TipRanks.com, Scala is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sanofi with a $78.98 average price target.
